0001140361-14-028181.txt : 20140710 0001140361-14-028181.hdr.sgml : 20140710 20140710174531 ACCESSION NUMBER: 0001140361-14-028181 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140708 FILED AS OF DATE: 20140710 DATE AS OF CHANGE: 20140710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 14970352 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 doc1.xml FORM 4 X0306 4 2014-07-08 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54, RUE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock 2014-07-08 4 P 0 9985 309.3301 A 21262726 I See note Common Stock 2014-07-08 4 P 0 37790 310.3359 A 21300516 I See note Common Stock 2014-07-08 4 P 0 42745 311.2548 A 21343261 I See note Common Stock 2014-07-08 4 P 0 17014 312.1152 A 21360275 I See note Common Stock 2014-07-08 4 P 0 32331 313.0924 A 21392606 I See note Common Stock 2014-07-08 4 P 0 8229 314.4147 A 21400835 I See note Common Stock 2014-07-08 4 P 0 4906 314.8523 A 21405741 I See note Common Stock 2014-07-09 4 P 0 15565 304.1935 A 21421306 I See note Common Stock 2014-07-09 4 P 0 20608 305.0939 A 21441914 I See note Common Stock 2014-07-09 4 P 0 6513 306.1305 A 21448427 I See note Common Stock 2014-07-09 4 P 0 14532 307.2219 A 21462959 I See note Common Stock 2014-07-09 4 P 0 14586 308.1936 A 21477545 I See note Common Stock 2014-07-09 4 P 0 26831 306.2766 A 21504376 I See note Common Stock 2014-07-09 4 P 0 62861 310.1031 A 21567237 I See note Common Stock 2014-07-09 4 P 0 29829 311.0768 A 21597066 I See note Common Stock 2014-07-09 4 P 0 3675 311.9096 A 21600741 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). The shares were purchased pursuant to a plan intended to comply with Rule 10b5-1(c)(1)(i) under the Exchange Act, entered into with a broker on June 27, 2014. Purchase prices range from $308.76 to $309.74 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 18,801,189 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $309.75 to $310.73 per share, inclusive. Purchase prices range from $310.75 to $311.74 per share, inclusive. Purchase prices range from $311.75 to $312.68 per share, inclusive. Purchase prices range from $312.74 to $313.68 per share, inclusive. Purchase prices range from $313.77 to $314.69 per share, inclusive. Purchase prices range from $314.79 to $315.00 per share, inclusive. Purchase prices range from $303.60 to $304.59 per share, inclusive. Purchase prices range from $304.61 to $305.59 per share, inclusive. Purchase prices range from $305.60 to $306.56 per share, inclusive. Purchase prices range from $306.65 to $307.63 per share, inclusive. Purchase prices range from $307.65 to $308.64 per share, inclusive. Purchase prices range from $308.65 to $309.63 per share, inclusive. Purchase prices range from $309.65 to $310.64 per share, inclusive. Purchase prices range from $310.67 to $311.65 per share, inclusive. Purchase prices range from $311.67 to $312.23 per share, inclusive. /s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 2014-07-10